Cargando…
FGFR1 is an adverse outcome indicator for luminal A breast cancers
Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Theref...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826266/ https://www.ncbi.nlm.nih.gov/pubmed/26673008 http://dx.doi.org/10.18632/oncotarget.6563 |
_version_ | 1782426319875735552 |
---|---|
author | Shi, Yu-Jie Tsang, Julia Y.S. Ni, Yun-Bi Chan, Siu-Ki Chan, Kui-Fat Tse, Gary M. |
author_facet | Shi, Yu-Jie Tsang, Julia Y.S. Ni, Yun-Bi Chan, Siu-Ki Chan, Kui-Fat Tse, Gary M. |
author_sort | Shi, Yu-Jie |
collection | PubMed |
description | Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Therefore, analysis of protein level may have more clinical relevance. We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient's survival. FGFR1 expression was associated mainly with luminal cancers, particularly luminal B subtype (23.5%; p < 0.001), and it also showed adverse prognostic impact on luminal A cancers. FGFR1 expression was associated with higher pN (p = 0.023), pT (p = 0.003) stages, lymphovascular invasion (p = 0.010), p-cadherin (p = 0.028), synaptophysin (p = 0.009) and SOX2 expression (p = 0.034) in luminal A cancers. FGFR1 expressing luminal A cancers showed a similar outcome as luminal B cancers. Multivariate Cox regression analysis demonstrated FGFR1 positive luminal A cancers to be an independently poor prognosticator for disease free survival in luminal cancers (hazard ratio = 3.341, p = 0.008). Thus FGFR1 could be useful in identifying the aggressive cases amongst heterogeneous luminal A cancers. Given the relevance of FGFR pathway in treatment resistance in luminal cancers, FGFR1 could be an important tumor biomarker and adverse prognostic factor potentially exploitable in the clinical management of luminal cancers. |
format | Online Article Text |
id | pubmed-4826266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-48262662016-05-09 FGFR1 is an adverse outcome indicator for luminal A breast cancers Shi, Yu-Jie Tsang, Julia Y.S. Ni, Yun-Bi Chan, Siu-Ki Chan, Kui-Fat Tse, Gary M. Oncotarget Clinical Research Paper Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Therefore, analysis of protein level may have more clinical relevance. We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient's survival. FGFR1 expression was associated mainly with luminal cancers, particularly luminal B subtype (23.5%; p < 0.001), and it also showed adverse prognostic impact on luminal A cancers. FGFR1 expression was associated with higher pN (p = 0.023), pT (p = 0.003) stages, lymphovascular invasion (p = 0.010), p-cadherin (p = 0.028), synaptophysin (p = 0.009) and SOX2 expression (p = 0.034) in luminal A cancers. FGFR1 expressing luminal A cancers showed a similar outcome as luminal B cancers. Multivariate Cox regression analysis demonstrated FGFR1 positive luminal A cancers to be an independently poor prognosticator for disease free survival in luminal cancers (hazard ratio = 3.341, p = 0.008). Thus FGFR1 could be useful in identifying the aggressive cases amongst heterogeneous luminal A cancers. Given the relevance of FGFR pathway in treatment resistance in luminal cancers, FGFR1 could be an important tumor biomarker and adverse prognostic factor potentially exploitable in the clinical management of luminal cancers. Impact Journals LLC 2015-12-11 /pmc/articles/PMC4826266/ /pubmed/26673008 http://dx.doi.org/10.18632/oncotarget.6563 Text en Copyright: © 2016 Shi et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Shi, Yu-Jie Tsang, Julia Y.S. Ni, Yun-Bi Chan, Siu-Ki Chan, Kui-Fat Tse, Gary M. FGFR1 is an adverse outcome indicator for luminal A breast cancers |
title | FGFR1 is an adverse outcome indicator for luminal A breast cancers |
title_full | FGFR1 is an adverse outcome indicator for luminal A breast cancers |
title_fullStr | FGFR1 is an adverse outcome indicator for luminal A breast cancers |
title_full_unstemmed | FGFR1 is an adverse outcome indicator for luminal A breast cancers |
title_short | FGFR1 is an adverse outcome indicator for luminal A breast cancers |
title_sort | fgfr1 is an adverse outcome indicator for luminal a breast cancers |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826266/ https://www.ncbi.nlm.nih.gov/pubmed/26673008 http://dx.doi.org/10.18632/oncotarget.6563 |
work_keys_str_mv | AT shiyujie fgfr1isanadverseoutcomeindicatorforluminalabreastcancers AT tsangjuliays fgfr1isanadverseoutcomeindicatorforluminalabreastcancers AT niyunbi fgfr1isanadverseoutcomeindicatorforluminalabreastcancers AT chansiuki fgfr1isanadverseoutcomeindicatorforluminalabreastcancers AT chankuifat fgfr1isanadverseoutcomeindicatorforluminalabreastcancers AT tsegarym fgfr1isanadverseoutcomeindicatorforluminalabreastcancers |